🇺🇸 FDA
Pipeline program

ALXN 2040, ALXN 2040

ALXN2040-PNH-302

Phase 3 small_molecule active

Quick answer

ALXN 2040, ALXN 2040 for Paroxysmal Nocturnal Hemoglobinuria is a Phase 3 program (small_molecule) at Alexion Europe SAS with 1 ClinicalTrials.gov record(s).

Program details

Company
Alexion Europe SAS
Indication
Paroxysmal Nocturnal Hemoglobinuria
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials